Rate of cancer progression as a predictive marker of efficacy of immunotherapy: An analysis in metastatic non-small-cell lung cancer

Thiru Prasanna, Mal Arasaratnam, Michael Boyer, Catriona McNeil, Megan B. Barnet, Rebecca Asher, Rina Hui, Adnan Nagrial, Steven Kao

Research output: Contribution to journalArticle

Abstract

Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into two groups: slow and rapid based on their ROP. Results: A total of 73 patients were eligible. Progression-free survival (PFS) was significantly shorter in rapid ROP, compared with slow (1.7 vs 4.8 months; HR: 2.42; 95% CI: 1.36-4.30; p = 0.008), as was the overall survival (OS; 5.6 vs 18.7 months; HR: 2.30; 95% CI: 1.13-4.69; p = 0.02). Overall response rate (40 vs 17%) was numerically higher in slow ROP than rapid (p = 0.19). PFS/OS did not correlate with the best response to their last chemotherapy or time to progression from previous line of therapy. Presence of a targetable mutation negatively correlated with PFS/OS. Conclusion: ROP prior to starting PD-1 inhibitors correlates with survival. PFS/OS were shorter in rapid ROP.

Original languageEnglish
Pages (from-to)657-665
Number of pages9
JournalImmunotherapy
Volume11
Issue number8
DOIs
Publication statusPublished - 15 May 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Disease-Free Survival
Neoplasms
Survival
Biomarkers
Drug Therapy
Mutation

Cite this

Prasanna, Thiru ; Arasaratnam, Mal ; Boyer, Michael ; McNeil, Catriona ; Barnet, Megan B. ; Asher, Rebecca ; Hui, Rina ; Nagrial, Adnan ; Kao, Steven. / Rate of cancer progression as a predictive marker of efficacy of immunotherapy: An analysis in metastatic non-small-cell lung cancer. In: Immunotherapy. 2019 ; Vol. 11, No. 8. pp. 657-665.
@article{d7a98eae56e5480ebe73f3b2ce57d573,
title = "Rate of cancer progression as a predictive marker of efficacy of immunotherapy: An analysis in metastatic non-small-cell lung cancer",
abstract = "Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into two groups: slow and rapid based on their ROP. Results: A total of 73 patients were eligible. Progression-free survival (PFS) was significantly shorter in rapid ROP, compared with slow (1.7 vs 4.8 months; HR: 2.42; 95{\%} CI: 1.36-4.30; p = 0.008), as was the overall survival (OS; 5.6 vs 18.7 months; HR: 2.30; 95{\%} CI: 1.13-4.69; p = 0.02). Overall response rate (40 vs 17{\%}) was numerically higher in slow ROP than rapid (p = 0.19). PFS/OS did not correlate with the best response to their last chemotherapy or time to progression from previous line of therapy. Presence of a targetable mutation negatively correlated with PFS/OS. Conclusion: ROP prior to starting PD-1 inhibitors correlates with survival. PFS/OS were shorter in rapid ROP.",
keywords = "immunotherapy, lung cancer, PD-1 inhibitor, predictive biomarker, rate of progression",
author = "Thiru Prasanna and Mal Arasaratnam and Michael Boyer and Catriona McNeil and Barnet, {Megan B.} and Rebecca Asher and Rina Hui and Adnan Nagrial and Steven Kao",
year = "2019",
month = "5",
day = "15",
doi = "10.2217/imt-2018-0180",
language = "English",
volume = "11",
pages = "657--665",
journal = "Immunotherapy",
issn = "1750-7448",
publisher = "Future Medicine Ltd",
number = "8",

}

Prasanna, T, Arasaratnam, M, Boyer, M, McNeil, C, Barnet, MB, Asher, R, Hui, R, Nagrial, A & Kao, S 2019, 'Rate of cancer progression as a predictive marker of efficacy of immunotherapy: An analysis in metastatic non-small-cell lung cancer', Immunotherapy, vol. 11, no. 8, pp. 657-665. https://doi.org/10.2217/imt-2018-0180

Rate of cancer progression as a predictive marker of efficacy of immunotherapy: An analysis in metastatic non-small-cell lung cancer. / Prasanna, Thiru; Arasaratnam, Mal; Boyer, Michael; McNeil, Catriona; Barnet, Megan B.; Asher, Rebecca; Hui, Rina; Nagrial, Adnan; Kao, Steven.

In: Immunotherapy, Vol. 11, No. 8, 15.05.2019, p. 657-665.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rate of cancer progression as a predictive marker of efficacy of immunotherapy: An analysis in metastatic non-small-cell lung cancer

AU - Prasanna, Thiru

AU - Arasaratnam, Mal

AU - Boyer, Michael

AU - McNeil, Catriona

AU - Barnet, Megan B.

AU - Asher, Rebecca

AU - Hui, Rina

AU - Nagrial, Adnan

AU - Kao, Steven

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into two groups: slow and rapid based on their ROP. Results: A total of 73 patients were eligible. Progression-free survival (PFS) was significantly shorter in rapid ROP, compared with slow (1.7 vs 4.8 months; HR: 2.42; 95% CI: 1.36-4.30; p = 0.008), as was the overall survival (OS; 5.6 vs 18.7 months; HR: 2.30; 95% CI: 1.13-4.69; p = 0.02). Overall response rate (40 vs 17%) was numerically higher in slow ROP than rapid (p = 0.19). PFS/OS did not correlate with the best response to their last chemotherapy or time to progression from previous line of therapy. Presence of a targetable mutation negatively correlated with PFS/OS. Conclusion: ROP prior to starting PD-1 inhibitors correlates with survival. PFS/OS were shorter in rapid ROP.

AB - Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into two groups: slow and rapid based on their ROP. Results: A total of 73 patients were eligible. Progression-free survival (PFS) was significantly shorter in rapid ROP, compared with slow (1.7 vs 4.8 months; HR: 2.42; 95% CI: 1.36-4.30; p = 0.008), as was the overall survival (OS; 5.6 vs 18.7 months; HR: 2.30; 95% CI: 1.13-4.69; p = 0.02). Overall response rate (40 vs 17%) was numerically higher in slow ROP than rapid (p = 0.19). PFS/OS did not correlate with the best response to their last chemotherapy or time to progression from previous line of therapy. Presence of a targetable mutation negatively correlated with PFS/OS. Conclusion: ROP prior to starting PD-1 inhibitors correlates with survival. PFS/OS were shorter in rapid ROP.

KW - immunotherapy

KW - lung cancer

KW - PD-1 inhibitor

KW - predictive biomarker

KW - rate of progression

UR - http://www.scopus.com/inward/record.url?scp=85065974247&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0180

DO - 10.2217/imt-2018-0180

M3 - Article

VL - 11

SP - 657

EP - 665

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-7448

IS - 8

ER -